Alpha Tau Medical Ltd · NASDAQ:DRTS
Alpha Tau Medical — Technical Presentation (May 2026)
52 slides from Alpha Tau Medical's technical presentation, May 2026
Slide 1: Revolutionary Alpha-Emitters Radiotherapy: Brain Tumors
Revolutionary Alpha-Emitters Radiotherapy: Brain Tumors 1
Slide 2: Disclaimer
Disclaimer This presentation (together with oral statements made in connection herewith, the "Presentation") is for informational purposes only to assist interested parties in making their own evaluation with respect to Alpha Tau Medical Ltd. (“Alpha Tau” or the “Company”). The information contained
Slide 3: Today's Presenters
Today’s Presenters Uzi Sofer Raphi Levy Robert Den, MD Joshua Palmer, MD CEO CFO CMO Professor, Radiation Oncology Alpha Tau Alpha Tau Alpha Tau Ohio State University Comprehensive Cancer Center – The James 3
Slide 4: Agenda
Agenda • Alpha DaRT Mechanism of Action • Preclinical Data • Clinical Approach • Clinical Trial 4
Slide 5: Anticipated Milestones
Anticipated Milestones Geography Target Indication H1 2026 H2 2026 2027+ ✓ Recurrent Complete Multi-Center Pivotal Data Readout + Potential FDA Potential FDA Cutaneous SCC Recruitment Submission Approval United Complete Pancreatic Cancer Initial Readout from Pilot Recruitment in Pilot States Study S
Slide 6: Alpha DaRT: Mechanism of Action
Alpha DaRT: Mechanism of Action 6
Slide 7: Types of Radioactive Decay
Types of Radioactive Decay Due to the mass of the alpha particle, in comparison to beta particle, alpha has a low penetration power. This means that the outside layer of the human skin, for example, can block these particles. 7
Slide 8: Why Use Alpha Radiation?
Why Use Alpha Radiation? Conventional Gamma/Beta Radiation Alpha Radiation • Indirectly damaging the DNA • Directly damaging the DNA • Dependent on oxygen presence • Independent of oxygen presence • Repairable single strand breaks • Irreparable double strand breaks γ/β Radiation Free O2 Radicals α R
Slide 9: Alpha Radiation is Focal - Short Range Limits Clinical Use
Alpha Radiation is Focal - Short Range Limits Clinical Use Beta/Gamma Radiation Alpha Radiation Long therapeutic range with risk to Short range in tissue limits damage surrounding organs to surrounding organs but also limits coverage Healthy Tissue Healthy Tissue What is the Alpha DaRT? 9
Slide 10: Alpha DaRT - Diffusing Alpha-emitters Radiation Therapy
Alpha DaRT - Diffusing Alpha-emitters Radiation Therapy https://www.youtube.com/watch?v=nwfzJHm0fTQ 10
Slide 11: Mechanism of Action of the Alpha DaRT Technology
Mechanism of Action of the Alpha DaRT Technology 224Ra Decay Chain Alpha DaRT leverages the innate decay chain of Radium-224 The decay chain of Radium-224 includes four alpha particles Radium-224 has a half-life of ~3.7 days, while the remaining decay chain has a total half-life of approximately 12
Slide 12: Brain Preclinical Studies – Small Animal
Brain Preclinical Studies – Small Animal 12
Slide 13: Alpha DaRT is Designed to be Highly Potent and Conformal
Alpha DaRT is Designed to be Highly Potent and Conformal Alpha DaRT observed activity range (U87 GBM s.c. tumors): A representative tumor section demonstrating (left) normalized asymptotic dose according to high-resolution autoradiography analysis, and (right) correlating necrotic domains following
Slide 14: In Vivo Impact of Alpha DaRT Monotherapy and in Combination with Temozolomide
In Vivo Impact of Alpha DaRT Monotherapy and in Combination with Temozolomide Mean Tumor Volume Inert + vehicle 700 (n=8) 600 DaRT + vehicle Tumor Volume (mm3) 500 (n=9) DaRT + TMZ 400 (n=7) 300 200 100 0 0 10 20 30 40 50 Days Post DaRT insertion Growth of U87 tumors (4 mm length) treated with a sin
Slide 15: Alpha DaRT + Avastin Combo Showed Attenuated Growth of GBM Xenografts
Alpha DaRT + Avastin Combo Showed Attenuated Growth of GBM Xenografts Alpha DaRT + Avastin 1,600 Alpha DaRT + IgG Inert + Avastin 1,400 Inert + IgG n=12 1,200 Tumor volume (mm3) 1,000 800 Alpha DaRT Insertion 600 n=13 400 n=13 n=14 200 0 0 5 10 15 20 25 30 35 40 Days Post Alpha DaRT Insertion Avasti
Slide 16: Alpha DaRT Can be Implanted Orthotopically
Alpha DaRT Can be Implanted Orthotopically 16
Slide 17: Brain Preclinical Studies – Large Animal
Brain Preclinical Studies – Large Animal 17
Slide 18: Alpha Radial Applicator
Alpha Radial Applicator https://www.youtube.com/watch?v=IJY965J0xMk 18
Slide 19: MR Image of an Alpha DaRT Source in a Phantom Model
MR Image of an Alpha DaRT Source in a Phantom Model A designated applicator allowed the delivery of 1-3 clusters of 7 sources in each hemisphere 19
Slide 20: Large Animal Pre-Clinical Trial of Brain Applicator
Large Animal Pre-Clinical Trial of Brain Applicator Surgical Insertion Intra-op Fluoroscope Post – Insertion CT Post – Coronal MRI Shushan, Yigal et al. “Stereotactic implantation of diffusing alpha-emitters radiation therapy sources in the swine brain: a potential new focal therapy for brain tumors
Slide 21: Highlights from Pre-Clinical Brain Studies
Highlights from Pre-Clinical Brain Studies Image-guided stereotactic Alpha DaRT deployment and implantation in the swine brain was demonstrated to be feasible and safe. The configuration required by the treatment plan was efficiently implemented using a designated applicator. In contrast to other ra
Slide 22: Interim Data: Alpha DaRT First Patients in CTP-GBM-01
Interim Data Alpha DaRT First 3 Patients in CTP-GBM-01 22
Slide 23: REGAIN Clinical Trial Design
REGAIN Clinical Trial Design Primary Endpoints: Treatment Protocol: • One-time treatment with Alpha DaRT Feasibility and Safety using the Alpha radial applicator Recurrent GBM Insertion • The patients will receive steroids to Secondary Endpoints: prevent edema or increase intracranial MRI Response a
Slide 24: Baseline Characteristics of First Three Patients Treated
Patient 1 Patient 2 Patient 3 Baseline Characteristics of First Three Patients Treated Patient 1 Patient 2 Patient 3 Age Recurrent GBM 56 71 56 Sex Male Male Male WHO grade 4 glioma IDH wild Right frontal WHO grade 4 WHO grade 4 glioma IDH wild Initial Diagnosis type, MGMT unmethylated with glioma I
Slide 25: Patient 1
Patient 1 Patient 2 Patient 3 Patient 1 • 56-year-old male with a WHO grade 4 glioma IDH wild type, MGMT unmethylated with FGFR:TACC fusion • Initial Diagnosis was in 2/2024, Gross Total Resection in 2/11/24 • Post operative course: • 60 Gy in 30 fractions with temozolomide completed 3/19/24-4/30/24
Slide 26: Pre-Alpha DaRT MRI
Patient 1 Patient 2 Patient 3 Pre-Alpha DaRT MRI • New focal enhancement in the right parieto- occipital lobe with surrounding FLAIR • Amino Acid PET performed and focal activity seen at these lesion only Ax T1 C+ Ax T2 FLAIR 26
Slide 27: Treatment Plan
Patient 1 Patient 2 Patient 3 Treatment Plan 27
Slide 28: Post Insertion Dosimetry
Patient 1 Patient 2 Patient 3 Post Insertion Dosimetry 28
Slide 29: Post Insertion Imaging: Patients 1, 2 and 3
Patient 1 Patient 2 Patient 3 Post Implant CT-Same Day Showing accurate placement of seeds, no bleed Post Implant MRI - Same Day showing Post Implant MRI - Dosimetry accurate placement of sources confirming appropriate coverage Pre-treatment PET demonstrating activity only in the new focal lesion Po
Slide 30: MRI 1 Month Post Alpha DaRT
Patient 1 Patient 2 Patient 3 MRI 1 Month Post Alpha DaRT • There was a focal enhancement around each Alpha DaRT • No discernable lesion remained • Confirmed on central neuroradiology review with 2 neuroradiologists • No new edema around implant 30
Slide 31: MRI 3 Months Post Alpha DaRT
Patient 1 Patient 2 Patient 3 MRI 3 Months Post Alpha DaRT • No progression of disease • Continued to be in CR • No new radiation treatment changes or injury • Alpha DaRT sources continued to have linear enhancement 31
Slide 32: Adverse Events and Current Status
Patient 1 Patient 2 Patient 3 Adverse Events and Current Status* • He developed no dose limiting toxicities, no symptoms from treatment • NED (no evidence of disease), with complete response (CR) in the lesion * Interim Data as of 3-May-2026 32
Slide 33: Patient 2
Patient 1 Patient 2 Patient 3 Patient 2 • 71-year-old male with an initial diagnosis in 5/2021 of a right frontal WHO grade 4 glioma IDH wild type, who underwent gross total resection and completed chemo-RT with 60 Gy in 30 fractions 6/21- 8/11/21 and temozolomide • The patient had seizures post sur
Slide 34: Prior Radiation Therapy Courses
Patient 1 Patient 2 Patient 3 Prior Radiation Therapy Courses 46 Gy with 14 Gy boost (60Gy) total 35 GyE in 10 fractions focal protons IMPT 34
Slide 35: Pre-Alpha DaRT MRI
Patient 1 Patient 2 Patient 3 Pre-Alpha DaRT MRI • New focal enhancement in the right frontal lobe with surrounding FLAIR • Amino Acid PET F18 Fluciclivine PET Ax T1 C+ performed and focal activity seen at these lesion only CT head no contrast Ax T2 FLAIR 35
Slide 36: Treatment Plan
Patient 1 Patient 2 Patient 3 Treatment Plan 36
Slide 37: Post Insertion Dosimetry
Patient 1 Patient 2 Patient 3 Post Insertion Dosimetry 37
Slide 38: Alpha DaRT Deployment
Patient 1 Patient 2 Patient 3 Alpha DaRT Deployment Post-op Day 0 MRI and CT demonstrating accurate deployment 38
Slide 39: MRI 1 Month Post Alpha DaRT
Patient 1 Patient 2 Patient 3 MRI 1 Month Post Alpha DaRT • There was a focal enhancement around each Alpha DaRT • No discernable lesion remained • Confirmed on central neuroradiology review with 2 neuroradiologists • No new edema around implant 39
Slide 40: MRI 3 Months Post Alpha DaRT
Patient 1 Patient 2 Patient 3 MRI 3 Months Post Alpha DaRT • No progression of disease • Continued to be in complete response • No new radiation treatment changes or injury • Alpha DaRT with continued but diminishing enhancement 40
Slide 41: Adverse Events
Patient 1 Patient 2 Patient 3 Adverse Events • He developed a grade 3 seizure with Todd’s paralysis 10 days post Alpha DaRT, this occurred during his steroid taper • This required a 48-hour hospitalization • As previously noted, the patient had a history of seizures • Symptoms improved to baseline o
Slide 42: Patient 3
Patient 1 Patient 2 Patient 3 Patient 3 • 56 yo M with WHO grade 4 glioma IDH wt, MGMT hypermethylated, Ki67-40%, DL1 0% • He underwent a subtotal resection and underwent a reoperation (gross total resection) 1 month later due to early progression noted on imaging, and developed post op empyema with
Slide 43: Prior Radiation Treatment Plan
Patient 1 Patient 2 Patient 3 Prior Radiation Treatment Plan 43
Slide 44: Pre-Alpha DaRT MRI
Patient 1 Patient 2 Patient 3 Pre-Alpha DaRT MRI • New focal enhancement in the right frontal lobe with surrounding FLAIR F18 Fluciclivine PET • Amino Acid PET performed and focal activity seen at these lesion only Ax T1 C+ Ax T2 FLAIR 44
Slide 45: Treatment Plan
Patient 1 Patient 2 Patient 3 Treatment Plan 45
Slide 46: Post Insertion Dosimetry
Patient 1 Patient 2 Patient 3 Post Insertion Dosimetry 46
Slide 47: Alpha DaRT Deployment
Patient 1 Patient 2 Patient 3 Alpha DaRT Deployment Post-op Day 0 MRI and CT demonstrating accurate deployment 47
Slide 48: Post Implant Day 3 MRI
Patient 1 Patient 2 Patient 3 Post Implant Day 3 MRI • 3 days post procedure and steroids patient had breakthrough seizure • MRI showed pseudoprogression with edema and enhancement slightly larger 48
Slide 49: MRI 1 Month Post Alpha DaRT
Patient 1 Patient 2 Patient 3 MRI 1 Month Post Alpha DaRT • There was a focal enhancement around each Alpha DaRT • 30% decrease in size • Confirmed on central neuroradiology review with 2 neuroradiologists • No new edema around Alpha DaRT 49
Slide 50: Adverse Events
Patient 1 Patient 2 Patient 3 Adverse Events* • He developed a grade 2 seizure • His symptoms improved to baseline on steroids and additional imaging showed normalizing edema to pretreatment extent • Doing well and back to his neurologic baseline • His most recent response was Stable Disease per RAN
Slide 51: Summary
Summary* • Three patients have been treated • There were no unanticipated associated side effects noted • All patients’ tumors have responded with 2 complete responses and one stable disease (30% size reduction) • Plan for completion of enrollment of 10 patients on this pilot study pending FDA revie
Slide 52: Questions?
AlphetAU ai Questions?
Alpha Tau Medical — Technical Presentation (May 2026) on 6ix